CytoDyn

CytoDyn’s PRO 140 for HIV rejected by FDA for Orphan Drug Designation

Thursday, April 20, 2017

CytoDyn, a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that its application for Orphan Drug Designation (ODD) was not granted by the Office of Orphan Products Development of the FDA because PRO 140 appears to have the potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested.

[Read More]

Ampio Pharmaceuticals appoints Gregory A. Gould CFO

Friday, June 6, 2014

Ampio Pharmaceuticals has appointed Gregory A. Gould chief financial officer, treasurer and corporate secretary. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10. Mark McGregor, the company’s current chief financial officer, will retire from Ampio Pharmaceuticals following a transition period later this year.

[Read More]